Roche’s CT-388 Produces Large Placebo-Adjusted Weight Loss in Phase II; Phase III Set to Begin This Quarter
Roche announced positive Phase II findings for CT-388, a dual GLP-1/GIP receptor agonist for people living with obesity. The investigational therapy delivered a 22.5% placebo-adjusted weight loss at 48 weeks and saw 54% of participants on the 24 mg dose reach resolution of obesity. Safety and tolerability were reported as generally consistent with …